|
|
|
Volumn , Issue OCT., 2002, Pages 11-
|
|
New antipsychotic, new benefits?
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ARIPIPRAZOLE;
CANNABINOID RECEPTOR;
CANNABINOID RECEPTOR AGONIST;
DOPAMINE AUTORECEPTOR;
DOPAMINE RECEPTOR;
DOPAMINE RECEPTOR BLOCKING AGENT;
EP 00367141;
EP 01145711;
ILOPERIDONE;
NEUROLEPTIC AGENT;
OLANZAPINE;
RISPERIDONE;
SEROTONIN ANTAGONIST;
SEROTONIN RECEPTOR;
SIGMA OPIATE RECEPTOR;
US 05006528;
ZIPRASIDONE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG MARKETING;
DRUG MECHANISM;
DRUG POTENCY;
DRUG SELECTIVITY;
DRUG SPECIFICITY;
DRUG TOLERABILITY;
HUMAN;
NOTE;
PATIENT COMPLIANCE;
PREVALENCE;
SCHIZOPHRENIA;
SIDE EFFECT;
TREATMENT OUTCOME;
UNITED STATES;
|
|
EID: 0036798863
PISSN: 14727463
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|